趙 鑫,施曉雷,馬虎成,丁義濤
(南京大學(xué)醫(yī)學(xué)院附屬鼓樓醫(yī)院肝膽外科,江蘇南京 210008)
抗中性粒細(xì)胞血清對D-氨基半乳糖誘導(dǎo)的急性肝衰竭大鼠的作用
趙 鑫,施曉雷,馬虎成,丁義濤
(南京大學(xué)醫(yī)學(xué)院附屬鼓樓醫(yī)院肝膽外科,江蘇南京 210008)
目的 研究D-氨基半乳糖(D-GalN)誘導(dǎo)的急性肝衰竭大鼠中性粒細(xì)胞的改變,探討以中性粒細(xì)胞為靶點(diǎn)的干預(yù)手段對急性肝衰竭的治療作用。方法 構(gòu)建D-GalN誘導(dǎo)的SD大鼠急性肝衰竭模型,觀察造模后大鼠肝功能、炎性因子(TNF-α、IL-1β)及外周血與肝臟中性粒細(xì)胞水平隨時(shí)間的變化。為觀察中性粒細(xì)胞的治療作用,將SD大鼠隨機(jī)分為3組:對照組、肝衰組及治療組(造模前24h尾靜脈注射抗中性粒細(xì)胞血清)。生化及血液分析儀檢測肝臟生化指標(biāo)(ALT、AST、TBIL、BA)及外周血中性粒細(xì)胞的數(shù)量及比率;免疫組化染色和Tunel染色分別檢測肝臟中性粒細(xì)胞數(shù)量及肝細(xì)胞凋亡水平;RT-PCR檢測肝臟組織炎性因子mRNA水平。結(jié)果 D-GalN誘導(dǎo)SD大鼠急性肝衰竭后6h血清ALT、AST、TBIL及BA較造模前顯著升高(P<0.05);肝臟組織中TNF-α、IL-1β的mRNA表達(dá)水平在造模后6h達(dá)到峰值(P<0.001),24h仍明顯高于造模前水平(P<0.001);外周血中性粒細(xì)胞數(shù)量、比率在造模后12h顯著增多(P<0.001),并至少持續(xù)至24h(P<0.001)。造模前24h尾靜脈注射抗中性粒細(xì)胞血清后,大鼠外周血及肝臟中性粒細(xì)胞數(shù)量在造模后24h較肝衰組明顯降低(P<0.001);同時(shí),血清ALT、AST、TBIL及BA較肝衰組顯著下降(P<0.05),肝臟組織凋亡細(xì)胞顯著減少,肝臟TNF-α、IL-1β表達(dá)水平也在治療后明顯下降(P<0.05)。結(jié)論D-GalN誘導(dǎo)的急性肝衰竭大鼠可出現(xiàn)外周血及肝臟中性粒細(xì)胞聚集,抗中性粒細(xì)胞血清可有效改善急性肝衰竭大鼠的肝功能及肝臟免疫微環(huán)境。
D-氨基半乳糖;急性肝衰竭;中性粒細(xì)胞;免疫微環(huán)境
優(yōu)先出版:http://www.cnki.net/kcms/detail/61.1399.R.20160202.1115.004.html(2016-02-02)ABSTRACT:Objective To investigate changes in the neutrophils in rats with D-galactosamine(D-GalN)-induced acute liver failure(ALF)and to explore the therapeutic effect of interventions treatment of neutrophils on ALF.Methods Liver function,the expressions of inflammatory cytokines TNF-αand IL-1β,and the changes of neutrophils in the peripheral blood and the liver were observed in rats with D-GalN(intraperitoneal injection)-induced ALF.SD rats were randomly divided into three groups when treated with intervention of neutrophils:control group,ALF group(intraperitoneal injection of D-GalN),and treatment group(intravenous injection of anti-PMN serum via tail vein 24 h before modeling).Biochemical analysis was used to detect serum ALT,AST,TBIL and blood ammonia.Hematology analyzer was applied to analyze the number and percentage of peripheral blood neutrophils.The number of neutrophils in the liver was evaluated by immunohistochemistry.Liver RT-PCR was adopted to detect the mRNA expression of inflammatory cytokines TNF-αand IL-1β.Results We found that 6 h after D-GalN injection,serum ALT,AST,TBIL and blood ammonia in ALF rats were significantly increased (P<0.05).The mRNA expression levels of inflammatory cytokines TNF-αand IL-1βin the liver reached the peak
急性肝功能衰竭(acute liver failure,ALF)是在沒有基礎(chǔ)肝臟疾病狀態(tài)下快速發(fā)生的肝細(xì)胞功能障礙,由于蛋白合成受損、凝血功能障礙、肝性腦病等多種嚴(yán)重并發(fā)癥的影響,目前除肝移植外尚缺乏有效的治療手段[1]。肝臟組織免疫微環(huán)境的失衡被認(rèn)為是ALF的重要發(fā)病機(jī)制,免疫調(diào)節(jié)相關(guān)的細(xì)胞及炎性因子在其中的作用亦得到大量研究的關(guān)注[2]。中性粒細(xì)胞在肝臟免疫微環(huán)境平衡中占有重要地位,在酒精性肝病、缺血再灌注損傷及內(nèi)毒素血癥所致的肝細(xì)胞損害中均可觀察到中性粒細(xì)胞的誘導(dǎo)作用[3-5]。中性粒細(xì)胞在急性肝功能衰竭狀態(tài)下可被募集至肝臟細(xì)胞,并出現(xiàn)“免疫麻痹”現(xiàn)象,進(jìn)而對肝組織及肝外組織形成直接損傷。研究認(rèn)為,這一過程可能伴隨著中性粒細(xì)胞介導(dǎo)的活性氧增多與肝竇區(qū)蛋白酶的聚集和激活[6],但其相關(guān)機(jī)制尚未有深入探討?;谄湓诟闻K免疫調(diào)控中的重要作用,本研究將觀察D-氨基半乳糖(D-galactosamine,D-GalN)誘導(dǎo)的SD大鼠ALF模型下中性粒細(xì)胞的狀態(tài)與功能改變,并通過外源性給予抗中性粒細(xì)胞血清探討其對ALF的肝臟功能及免疫微環(huán)境的影響。
1.1 實(shí)驗(yàn)動(dòng)物及分組 健康雄性SD大鼠,無特定病原體級,體質(zhì)量(200±20)g,由南京大學(xué)醫(yī)學(xué)院附屬鼓樓醫(yī)院實(shí)驗(yàn)動(dòng)物中心提供。56只SD大鼠禁食12h后,以800mg/kg濃度腹腔注射由等滲生理鹽水稀釋的D-GalN誘導(dǎo)急性肝衰竭模型,分別于造模后0、6、12、24、72、120、168h處死大鼠,收集大鼠外周血及肝臟組織待測。另將27只SD大鼠隨機(jī)分為3組:對照組、肝衰竭、治療組。對照組:在相應(yīng)造模時(shí)間腹腔注射等量等滲生理鹽水;肝衰組:實(shí)驗(yàn)動(dòng)物予禁食12h后,以800mg/kg濃度腹腔注射由等滲生理鹽水稀釋的D-GalN;治療組:建立急性肝衰竭模型前24h經(jīng)大鼠尾靜脈注射0.8mL兔抗大鼠中性粒細(xì)胞血清。在誘導(dǎo)急性肝衰竭模型24h后處死大鼠,收集大鼠外周血及肝臟組織待測。
1.2 主要試劑 D-氨基半乳糖購自南京博源醫(yī)藥科技有限公司,兔抗大鼠中性粒細(xì)胞血清購自加拿大Cedarlane公司,Tunel試劑盒及MPO抗體購自美國Gibco公司,RNA提取試劑盒購自北京百泰克生物技術(shù)有限公司,RT-PCR相關(guān)試劑盒購自日本TaKa-Ra Bio公司。
1.3 主要檢測手段
1.3.1 血液檢測 大鼠血清谷丙轉(zhuǎn)氨酶(ALT)、谷草轉(zhuǎn)氨酶(AST)和總膽紅素(TBIL)水平由全自動(dòng)生物化學(xué)分析儀(AU5421,BD公司)檢測,大鼠的外周血中性粒細(xì)胞數(shù)量及比率由血液分析儀(XE-5000,美國Sysmex公司)檢測,血氨(BA)由干式生化分析儀(VITROS 5.1FS,美國強(qiáng)生公司)檢測。
1.3.2 髓過氧化物酶(myeloperoxidase,MPO)免疫組化及Tunel染色 肝臟組織常規(guī)石蠟包埋,連續(xù)切片,常規(guī)脫蠟、復(fù)水,分別按MPO免疫組化試劑盒及Tunel檢測試劑盒的操作步驟進(jìn)行染色。封片后于顯微鏡下觀察MPO著色細(xì)胞及凋亡細(xì)胞數(shù)量的變化。
1.3.3 炎性因子及趨化因子的實(shí)時(shí)熒光定量PCR檢測 肝臟組織總RNA提取使用Bio Teke離心柱型高純度快速提取試劑盒,逆轉(zhuǎn)錄過程使用Prime-ScriptTM RT Master Mix試劑盒,TNF-α、IL-1β的mRNA表達(dá)水平檢測以β-actin作為管家基因,使用SYBR?Premix Ex TaqTM試劑盒及StepOne-PlusTM實(shí)時(shí)熒光定量PCR儀,所需引物均參考相應(yīng)文獻(xiàn),由南京金斯瑞公司合成。TNF-α:上游引物5′-GCTCCCTCTCATCAGTTCCA-3′,下游引物5′-GGCTTGTCACTCGAGTTTTGA-3′;IL-1β:上游引物5′-CAGGAAGGCAGTGTCACTCA-3′,下游引物5′-AGACAGCACGAGGCATTTTT-3′;β-actin:上游引物5′-CTGTCCCTGTATGCCTCTG-3′,下游引物5′-ATGTCACGCACGATTTCC-3′。
1.4 統(tǒng)計(jì)學(xué)方法 使用SPSS19.0統(tǒng)計(jì)學(xué)軟件進(jìn)行數(shù)據(jù)處理。實(shí)驗(yàn)結(jié)果采用均數(shù)±標(biāo)準(zhǔn)差(珔x±s)表示。對造模后不同時(shí)間點(diǎn)的比較采用重復(fù)測量的方差分析,對造模后24h不同干預(yù)組的組間比較,采用單因素方差分析。P<0.05為兩組具有統(tǒng)計(jì)學(xué)意義。
2.1 D-GalN誘導(dǎo)的急性肝衰竭SD大鼠肝功能及肝臟組織炎性因子TNF-α、IL-1β水平的變化 本研究檢測了D-GalN誘導(dǎo)的急性肝衰竭SD大鼠造模前(0h)及造模后6、12、24、72、120、168h共計(jì)7個(gè)時(shí)間點(diǎn)肝功能及炎性因子TNF-α、IL-1β水平變化。結(jié)果顯示,反映肝功能的生化指標(biāo)的ALT、AST、TBIL及BA在造模后6h即顯著升高(P<0.05),ALT、AST 于24h達(dá)到峰值,造模后168h可恢復(fù)至造模前水平(P>0.05);而TBIL及BA 72h達(dá)到峰值(表1)。肝臟組織中炎性因子TNF-α、IL-1β的mRNA表達(dá)水平在造模后6h即達(dá)到峰值(P<0.001),隨后逐漸下降,至造模后72h起表達(dá)與造模前相比無統(tǒng)計(jì)學(xué)差異(P>0.05,圖1)。
表1 急性肝衰竭大鼠造模后血清ALT、AST、TBIL及BA的變化Tab.1 Changes of serum ALT,AST,TBIL and blood ammonia in ALF rats (珔x±s)
圖1 急性肝衰竭大鼠造模后肝臟TNF-α及IL-1β表達(dá)水平的變化Fig.1Changes of TNF-αand IL-1βin the liver of ALF rats(珔x±s)
2.2 D-GalN誘導(dǎo)的急性肝衰竭SD大鼠外周血及肝臟中性粒細(xì)胞的變化 在D-GalN誘導(dǎo)的急性肝衰竭SD大鼠造模前(0h)及造模后12、24、72h共4個(gè)時(shí)間點(diǎn)通過血液分析儀檢測外周血中性粒細(xì)胞數(shù)量及比率。結(jié)果顯示,造模后12h外周血中性粒細(xì)胞數(shù)量及比率均顯著上升(P<0.001);24h有所下降,但仍明顯高于造模前水平(P<0.001);至72h兩者與造模前相比無統(tǒng)計(jì)學(xué)差異(P>0.05,表2)。免疫組化結(jié)果提示,肝臟MPO陽性中性粒細(xì)胞數(shù)量于造模后12h顯著增多,造模后72h出現(xiàn)下降,但較造模前仍明顯升高(圖2)。
表2 急性肝衰竭大鼠造模后外周血中性粒細(xì)胞數(shù)量及比率的變化Tab.2 Changes of the number and percentage of peripheral blood neutrophils in ALF rats (珔x±s)
2.3 外源性給予抗中性粒細(xì)胞血清對急性肝衰竭大鼠外周血與肝臟中性粒細(xì)胞、肝功能及肝臟組織炎性因子TNF-α、IL-1β的影響 在尾靜脈給予抗中性粒細(xì)胞血清后24h建立了D-GalN誘導(dǎo)的SD大鼠急性肝衰竭模型,并檢測了造模后24h大鼠外周血與肝臟中性粒細(xì)胞、肝功能及TNF-α、IL-1β的改變。結(jié)果發(fā)現(xiàn),抗中性粒細(xì)胞血清預(yù)治療組外周血中性粒細(xì)胞數(shù)量較肝衰組顯著降低(P<0.001,圖3),肝臟組織中性粒細(xì)胞數(shù)量較肝衰組也明顯減少(圖4);血清ALT、AST、TBIL及BA較肝衰組出現(xiàn)明顯回落(P<0.05,表3);與肝衰組相比較,中性粒細(xì)胞耗竭后Tunel陽性凋亡肝細(xì)胞數(shù)量明顯減少(圖5);同時(shí),肝臟組織炎性因子TNF-α、IL-1β的mRNA表達(dá)水平也在治療后明顯下降(P<0.05,圖6)。
圖2 急性肝衰竭大鼠造模后肝臟中性粒細(xì)胞數(shù)量的變化Fig.2Changes of the number of neutrophils in the liver of ALF rats
圖4 抗中性粒細(xì)胞血清治療對急性肝衰竭大鼠肝臟中性粒細(xì)胞數(shù)量的影響Fig.4The effect of anti-PMN serum treatment on the number of neutrophils in the liver of ALF rats棕染細(xì)胞為中性粒細(xì)胞;A:對照組;B:肝衰組;C:治療組。
急性肝功能衰竭在臨床普遍表現(xiàn)為迅速出現(xiàn)的肝細(xì)胞功能障礙,伴全身不可控的炎性反應(yīng)。通過建立D-GalN誘導(dǎo)的SD大鼠急性肝功能衰竭模型我們發(fā)現(xiàn),肝衰大鼠肝功能生化指標(biāo)ALT、AST、TBIL及BA均在短時(shí)間內(nèi)顯著增高,同時(shí)炎性因子TNF-α 與IL-1β在肝臟的表達(dá)于造模后6h達(dá)到峰值,并長時(shí)間維持在較高水平。我們的結(jié)果與急性肝功能衰竭的臨床癥狀高度相符,也提示了免疫微環(huán)境在急性肝衰竭進(jìn)展中的作用。TNF-α、IL-1β、IL-6等炎性因子在免疫調(diào)節(jié)中參與了中性粒細(xì)胞的招募與凋亡[7],進(jìn)入炎性組織的中性粒細(xì)胞可在高濃度促炎因子的快速誘導(dǎo)下釋放大量活性氧、蛋白酶和生長因子,從而破壞靶組織的完整性,這種類似正反饋的作用形式在許多炎癥性疾病中得到證實(shí)[8];另一方面,MPO的變化代表著中性粒細(xì)胞的功能及活性狀態(tài)。MPO可在吞噬細(xì)胞內(nèi)殺滅微生物,還可釋放到胞外直接破壞靶物質(zhì),對機(jī)體免疫調(diào)節(jié)發(fā)揮重要作用[9]。臨床調(diào)查進(jìn)一步提示,急性肝衰竭患者外周血中性粒細(xì)胞的吞噬功能顯著下降,其程度與患者預(yù)后呈明顯相關(guān)性[6]。動(dòng)物實(shí)驗(yàn)也發(fā)現(xiàn),急性肝衰竭狀態(tài)下壞死肝細(xì)胞的DNA和線粒體產(chǎn)物可招募中性粒細(xì)胞,并促進(jìn)中性粒細(xì)胞的肝內(nèi)堆積[10]。我們的結(jié)果也顯示,建立D-GalN誘導(dǎo)的大鼠急性肝衰竭模型后12h,外周血中性粒細(xì)胞數(shù)量及比率均顯著增加,并至少持續(xù)至造模后24h;同時(shí),急性肝衰竭大鼠肝臟內(nèi)MPO陽性中性粒細(xì)胞數(shù)量在造模后早期即顯著增多,表明中性粒細(xì)胞呈現(xiàn)高活化狀態(tài)。
表3 抗中性粒細(xì)胞血清對急性肝衰竭大鼠血清ALT、AST、TBIL及BA水平的影響Tab.3 The effect of anti-PMN serum on serum ALT,AST,TBIL and blood ammonia in ALF rats(珔x±s)
圖5 抗中性粒細(xì)胞血清治療對急性肝衰竭大鼠肝細(xì)胞凋亡的影響Fig.5The effect of anti-PMN serum treatment on hepatocyte apoptosis in ALF rats
圖6 抗中性粒細(xì)胞血清治療對急性肝衰竭大鼠肝臟TNF-α及IL-1β含量的影響Fig.6The effect of anti-PMN serum treatment on TNF-αand IL-1βin the liver of ALF rats(珔x±s)
中性粒細(xì)胞的活化及其在肝臟組織中的聚積可加重肝組織損傷。研究發(fā)現(xiàn),使用中性粒細(xì)胞表面受體抑制劑可顯著減輕中性粒細(xì)胞相關(guān)的免疫損傷,有助于肝臟組織修復(fù)[11]。因此,通過抑制中性粒細(xì)胞在肝內(nèi)的異常聚積和活化可能成為治療急性肝衰竭的關(guān)鍵環(huán)節(jié)。本研究采用尾靜脈外源性給予抗中性粒細(xì)胞血清來耗竭中性粒細(xì)胞,并觀察其在急性肝衰竭中的作用。我們的結(jié)果顯示,造模前24h注射抗中性粒細(xì)胞血清可顯著減少D-GalN誘導(dǎo)的急性肝衰竭大鼠外周血及肝臟中性粒細(xì)胞數(shù)量,提示該干預(yù)手段可有效逆轉(zhuǎn)急性肝衰狀態(tài)下肝臟中性粒細(xì)胞的聚集及活化。隨后我們觀察了中性粒細(xì)胞耗竭對急性肝衰竭大鼠的影響,發(fā)現(xiàn)抗中性粒細(xì)胞血清治療組在造模后24h可明顯降低包括ALT、AST、TBIL及BA在內(nèi)的肝臟生化指標(biāo),顯著減輕急性肝衰竭大鼠肝細(xì)胞的凋亡比率,同時(shí)下調(diào)炎性因子TNF-α與IL-1β在肝臟的mRNA表達(dá),有效改善了肝臟的免疫微環(huán)境。
綜上所述,在D-GalN誘導(dǎo)的SD大鼠急性肝功能衰竭中外周血及肝臟中性粒細(xì)胞明顯增多,通過耗竭外周血中性粒細(xì)胞可降低細(xì)胞凋亡及炎性因子表達(dá)。提示中性粒細(xì)胞浸潤可能是加重肝損傷的關(guān)鍵因素,以中性粒細(xì)胞為靶點(diǎn)的干預(yù)手段可改善肝臟免疫微環(huán)境,為急性肝功能衰竭的治療提供新的思路。
[1]MCPHAIL MJ,KRIESE S,HENEGHAN MA.Current management of acute liver failure[J].Curr Opin Gastroenterol,2015,31(3):209-214.
[2]WU Z,HAN M,CHEN T,et al.Acute liver failure:mechanisms of immune-mediated liver injury[J].Liver Int,2010,30 (6):782-794.
[3]JAESCHKE H.Mechanisms of liver injury.II.Mechanisms of neutrophil-induced liver cell injury during hepatic ischemiareperfusion and other acute inflammatory conditions[J].Am J Physiol Gastrointest Liver Physiol,2006,290(6):G1083-G1088.
[4]RAMAIAH SK,JAESCHKE H.Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury[J].Toxicol Mech Methods,2007,17(7):431-440.
[5]ROSE R,BANERJEE A,RAMAIAH SK.Characterization of a lipopolysaccharide mediated neutrophilic hepatitis model in Sprague Dawley rats[J].J Appl Toxicol,2007,27(6):602-611.
[6]TAYLOR NJ,NISHTALA A,MANAKKAT VIJAY GK,et al.Circulating neutrophil dysfunction in acute liver failure[J].Hepatology,2013,57(3):1142-1152.
[7]ZHOU H,LAPOINTE BM,CLARK SR,et al.A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide[J].J Immunol,2006,177(11):8103-8110.
[8]ABU-AMARA M,YANG SY,TAPURIA N,et al.Liver ischemia/reperfusion injury:processes in inflammatory networks—a review[J].Liver Transpl,2010,16:1016-1032.
[9]ALLEN RC,STEPHENS JT JR.Myeloperoxidase selectively binds and selectively kills microbes[J].Infect Immun,2011,79(1):474-485.
[10]MARQUES PE,AMARAL SS,PIRES DA,et al.Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure[J].Hepatology,2012,56(5):1971-1982.
[11]MARQUES PE,OLIVEIRA AG,PEREIRA RV,et al.Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice[J].Hepatology,2015,61(1):348-360.
(編輯 卓選鵬)(編輯 邱 芬)
Effect of anti-PMN serum treatment on D-GalN-induced ALF rats
ZHAO Xin,SHI Xiao-lei,MA Hu-cheng,DING Yi-tao
(Department of Hepatobiliary Surgery,the Affiliated Drum Tower Hospital of Nanjing University Medical School,Nanjing 210008,China)
at 6 h after modeling(P<0.001),and it was still notably higher at 24 h than before modeling(P<0.001).The number and percentage of peripheral blood neutrophils and the number of neutrophils in the liver were all markedly increased 12 h after modeling(P<0.001),and the increase continued at least until 24 h(P<0.001).24 h after intravenous injection of anti-PMN serum via tail vein,ALF rats had a distinct decrease in the number of peripheral blood neutrophils and neutrophils in the liver 24 h after modeling(P<0.001).Meanwhile,serum ALT,AST,TBIL and blood ammonia were all greatly decreased compared with those in ALF group(P<0.05);a significant reduction of hepatocyte apoptosis was observed.Also,the expressions of TNF-αand IL-1βin the liver were remarkably decreased after treatment(P<0.05).Conclusion Neutrophils accumulated in peripheral blood and liver of rats with D-GalN-induced ALF.The treatment of anti-PMN serum may have a therapeutic effect on liver function and immune microenvironment in ALF rats.
D-galactosamine(D-GalN);acute liver failure;neutrophil;immune microenvironment
R575.3
A
10.7652/jdyxb201602015
2015-05-18
2015-11-11
國家自然科學(xué)基金資助項(xiàng)目(No.81170418),江蘇省自然科學(xué)基金資助項(xiàng)目(No.BK20131084),中科院戰(zhàn)略先導(dǎo)計(jì)劃(No.XDA01030602)Supported by the National Natural Science Foundation of China(No.81170418),the Natural Science Foundation of Jiangsu Province (No.BK20131084),and Strategic Priority Research Program of the Chinese Academy of Sciences(No.XDA01030602)
丁義濤.E-mail:yitaoding@hotmail.com
book=225,ebook=74
西安交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版)2016年2期